MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Validity and reliability of muscle peak power testing in persons with Parkinson’s disease

F. Jensen, M. Langeskov-Christensen, L. Hvid, U. Dalgas (Aarhus, Denmark)

Meeting: 2023 International Congress

Abstract Number: 1867

Keywords: Rehabilitation

Category: Physical Therapy, Speech Therapy, Rehabilitation

Objective: We investigated the construct and ecological validity ON medication and the test-retest reliability both ON and OFF medication of the linear encoder lower extremity muscle peak power test in pwPD

Background: Persons with Parkinson’s disease (pwPD) experience impaired muscle function, possibly affecting their daily activities. Lower extremity muscle peak power is an important marker for physical function in pwPD. An easy-to-apply equipment that assesses peak power is a linear encoder which can be used in research and clinical practice. However, no study has investigated the validity and test-retest reliability (i.e., day-to-day variation) of the linear encoder lower extremity muscle peak power test in pwPD.

Method: Linear encoder data were collected while performing a sit-to-stand test. Construct validity (i.e. hypothesis testing of known groups validity) was assessed by comparing peak power from 69 pwPD and 35 healthy controls (HC). Ecological validity was evaluated by comparing associations between peak power and maximal force (Fmax) with walking performance (i.e., 6-minute walk test, Timed Up and Go test, and Six-Spot Step Test). Reliability was examined for 20 pwPD who completed 4 sit-to-stand tests (2 tests ON and 2 tests OFF medication), in a randomized order, separated by 5 to 11 days. Reliability was assessed as day-to-day variation and by intraclass correlation coefficients (ICC).

Results: Peak power was comparable between pwPD and HC (-1.1 W/kg; 95%-CI: -2.8;0.5). Stronger associations with functional performance were observed for peak power (r2=0.44-0.51) compared to Fmax (r2=0.25-0.29). Day-to-day variation was 1.0 and 1.3 W/kg and ICC2.1 was 0.95 (95%-CI: 0.87;0.98) and 0.93 (95%-CI: 0.82;0.97) ON and OFF medication, respectively.

Conclusion: The linear encoder lower extremity muscle peak power test is ecological valid but not construct valid ON medication and has an excellent day-to-day reliability ON and OFF medication.

To cite this abstract in AMA style:

F. Jensen, M. Langeskov-Christensen, L. Hvid, U. Dalgas. Validity and reliability of muscle peak power testing in persons with Parkinson’s disease [abstract]. Mov Disord. 2023; 38 (suppl 1). https://www.mdsabstracts.org/abstract/validity-and-reliability-of-muscle-peak-power-testing-in-persons-with-parkinsons-disease/. Accessed May 13, 2025.
  • Tweet
  • Email
  • Print

« Back to 2023 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/validity-and-reliability-of-muscle-peak-power-testing-in-persons-with-parkinsons-disease/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Patients with Essential Tremor Live Longer than their Relatives
  • #23624 (not found)
  • The hardest symptoms that bother patients with Parkinson's disease
  • Three cases of early tremor in the course of Guillain-Barré Syndrome
  • The impact of gastric acid suppressants and antacids on levodopa plasma concentration in patients with Parkinson’s disease
  • To be or not to bupropion: a drug-induced parkinsonism?
  • The Role of MRI and DaTscan in Vascular Parkinsonism: A Case Report
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley